ClinicalTrials.gg
CompletedNCT03316586Updated Dec 28, 2021Results posted

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

A Phase 2 interventional study of Nivolumab and Cabozantinib in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-28.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.

Enrollment
17th of 22
18 · median 47
Started
2017
with 3 others
Phase 2
15 of 22
1 open now
Registered
7th of 22
by date
Lead sponsor
3 of 22
Dana-Farber Cancer Institute

Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is one of 15 in phase 2, and was the 7th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing nivolumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer.

The drugs involved in this study are:

  • Cabozantinib (XL184)
  • Nivolumab
Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved the combination of Nivolumab and Cabozantinib as a treatment for any disease.

The FDA has not approved Cabozantinib for this specific disease but it has been approved for other uses. The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for this specific disease but it has been approved for other uses.

Cabozantinib has been used in some phase I studies and information from those other research studies suggests that cabozantinib may help to shrink or stabilize breast cancer.

Cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. An antibody is a natural protein made by the immune system that binds other proteins and molecules to fight infection and its ill effects. Antibodies stimulating the immune system have been developed for treatment of human cancers. Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.

In this research study, the investigators are looking at how the participant's type of breast cancer responds to the combination of cabozantinib and nivolumab.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed invasive breast cancer, with disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.
  • Estrogen-receptor and progesterone-receptor expression both \<10% by immunohistochemistry (IHC) and human epidermal growth factor receptor 2 () negative by IHC or non-amplified as determined by the current American Society of Clinical Oncology (ASCO)/CAP (College of American Pathologists) criteria. If patient has more than one histological result, the most recent one has to be considered for inclusion.
  • Participants must have by version 1.1
  • Participants must agree to undergo a research , if tumor is safely accessible, at baseline and 7-14 days prior to Cycle 3 Day 1. Participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) may submit an archived specimen.

Note: After the first 6 participants undergo biopsy on cabozantinib, we will review their adverse event profiles to ensure no more than a 20% rate of grade 3 or higher bleeding or wound healing complications occur. If more than 2 patients (>20%) have safety concerns, we will reassess the safety of collecting the research biopsies. Full review of all grade (including grade 1 and 2) may also prompt changes and will be reviewed by the study team. Exelixis may be consulted if necessary.

  • Prior chemotherapy: Participants may have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days prior to registration. Participants should also be adequately recovered from acute toxicities of prior treatment.
  • Prior biologic therapy: Patients must have discontinued all biologic therapy at least 14 days prior to registration.
  • Prior radiation therapy: Patients may have received prior radiation therapy in either the metastatic or early-stage setting. Radiation therapy must be completed per the following timelines:

    • Radiotherapy to the thoracic cavity or abdomen within 4 weeks prior to registration.
    • Radiotherapy to bone lesions within 2 weeks prior to registration.
    • Radiotherapy to any other site within 4 weeks prior to registration.
  • In all cases, there must be complete recovery and no ongoing complications from prior radiotherapy.
  • The subject is ≥18 years old.
  • (Eastern Cooperative Oncology Group) performance status ≤1( ≥60%, see Appendix A)
  • Participants must have normal organ and marrow function as defined below:

    • ≥1,000/microliter (mcL)
    • ≥100,000/mcL
    • ≥ 9 g/dl
    • total ≤1.5 × institutional (ULN) (or 2.0 x ULN in patients with documented Gilbert's Syndrome)
    • (AST) / Alanine transaminase (ALT) ≤2.5 × institutional ULN or ≤ 3 × institutional ULN for participants with documented liver metastases
    • creatinine \<1.5 ×institutional ULN OR ≥40 mL/min (using Cockcroft-Gault formula) for participants with creatinine levels above institutional ULN.
    • Urine protein/creatinine ratio (UPCR) ≤1
  • Female subjects of must have a negative pregnancy test at screening
  • Childbearing potential is defined as: participants who have not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus).
  • Female and male participants of childbearing potential must agree to use an adequate method of . Contraception is required starting with the first dose of study medication through 150 days (5 months) after the last dose of study medication . Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment.
  • The participant is capable of understanding and complying with the protocol and has signed the document

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. No ongoing complications from prior surgery are not eligible.
  • The participant has tumor in contact with, invading, or encasing major blood vessels or radiographic evidence of significant cavitary pulmonary lesions.
  • The subject has pathologic evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib;
  • Concurrent administration of other anti-cancer therapy within 14 days of starting protocol therapy and during the course of this study.
  • The participant has received another agent within 14 days of the first dose of study drug.
  • The participant has received a prior c-Met inhibitor
  • Has received prior therapy with an anti-programmed cell death-1 (), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
  • Known that are untreated, symptomatic, or require therapy to control symptoms. Participants with a history of treated central nervous system (CNS) are eligible. Treated brain metastases are defined as those having no evidence of progression for ≥ 1 month after treatment, and no ongoing requirement for , as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) completed during screening. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥2 weeks prior to registration. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Participants with CNS metastases treated by neurosurgical resection or brain performed within 2 months before day 1 will be excluded.
  • The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders including:
    • Congestive heart failure (CHF): (NYHA) Class III (moderate) or Class IV (severe) at the time of screening;
    • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment;
    • Any history of congenital long syndrome;
    • Any of the following within 6 months before the first dose of study treatment:
    • unstable angina pectoris;
    • clinically-significant cardiac arrhythmias;
    • stroke (including (TIA), or other ischemic event);
    • myocardial infarction;
    • GI disorders particularly those associated with a high risk of perforation or fistula formation including:
    • Tumors invading the GI tract, active peptic ulcer disease, active inflammatory bowel disease (eg, Crohn's disease), active diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction
    • Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before randomization, Note: Complete healing of an intra-abdominal abscess must be confirmed prior to randomization
  • Other clinically significant disorders that would preclude safe study participation;
  • Corrected Fridericia's QT interval (QTcF) interval >500 msec Note: Three ECGs must be performed for eligibility determination. If the average of these three consecutive results for QTcF is ≤ 500 msec, the subject meets eligibility in this regard.
  • Thromboembolic events requiring therapeutic anticoagulation. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors), inhibitors (eg, clopidogrel) are prohibited.

Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low molecular weight heparin (LMWH) are permitted (in subjects who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor).

Note: Subjects with a venous filter (eg vena cava filter) are not eligible for this study).

  • Individuals with a history of different are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy.
  • Participant has an active infection requiring IV antibiotics
  • Patient has a medical condition that requires chronic systemic steroid therapy or on any other form of medication. For example, participants with disease that requires systemic steroids or immunosuppression agents should be excluded. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • The participant is known to be positive for the (HIV), HepBsAg, or virus (HCV) RNA. HIV-positive participants on combination antiretroviral therapy are ineligible.
  • Known to any of the components of cabozantinib or nivolumab.
  • The participant has received a within 28 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, bacille Calmette-Guerin (BCG), and typhoid vaccine. The use of the inactivated seasonal influenza vaccine (Fluzone®) is allowed.
  • The subject has experienced any of the following:

    • Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment
    • Clinically significant hemoptysis within 3 months of the first dose of study treatment
    • Any other signs indicative of pulmonary hemorrhage within 3 months before the start of study treatment
  • The participant is unable to swallow oral dosage forms.
  • The participant is pregnant or breastfeeding
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Nivolumab + Cabozantinib

    * Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter * Cabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.

    Drug: Nivolumab · Drug: Cabozantinib

Interventions

  • Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.

    Also known as: Opdivo

  • Cabozantinib may help to shrink or stabilize breast cancer

    Also known as: Cabometyx

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) is defined as the percentage of patients with complete or partial response evaluated by RECIST 1.1. Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 2 years

Secondary outcomes

  1. Number of Participants With Adverse Events

    Toxicities will be defined according to NCI CTCAE, Version 4.0

    Time frame: 2 years

  2. Clinical Benefit Rate

    Clinical Benefit Rate (CBR) will be determined by looking at the number of subjects who have either a complete response, partial response, or stable disease for greater than or equal to 24 weeks, per RECIST 1.1

    Time frame: 2 years

  3. Progression Free Survival Rate

    Progression free survival is defined from the study entry to first documented evidence of disease progression by RECIST 1.1 or death of any cause, whichever occurs first. Patients alive with no progression are censored at the last disease assessment.

    Time frame: 5 years

  4. Overall Response Rate Per Immune Criteria

    ORR will be determined according to immune-related response criteria (irRC). Per irRC, irComplete Response (irCR) refers to complete disappearance of all target lesions. irPartial Response (irPR) refers to decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all target and all new measurable target lesions (i.e., Percentage Change in Tumor Burden). ORR per irRC is irCR + irPR.

    Time frame: 2 years

07

Results

Posted Dec 28, 2021
Limitations and caveats
Only one of the first 18 patients had a PR. The study therefore did not meet the prespecified criteria to proceed to the second stage of the trial, and it was closed to further accrual.

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Cabozantinib
Started18
Completed0
Not completed18
Withdrew: Adverse event2
Withdrew: Physician decision3
Withdrew: Lack of efficacy10
Withdrew: Still on treatment1
Withdrew: Patient needed radiation therapy1
Withdrew: Physician decision to send patient for breast surgery1

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) is defined as the percentage of patients with complete or partial response evaluated by RECIST 1.1. Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
2 years
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsNivolumab + Cabozantinib
Overall Response Rate1
SecondaryNumber of Participants With Adverse Events

Toxicities will be defined according to NCI CTCAE, Version 4.0

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsNivolumab + Cabozantinib
Number of Participants With Adverse Events18
SecondaryClinical Benefit Rate

Clinical Benefit Rate (CBR) will be determined by looking at the number of subjects who have either a complete response, partial response, or stable disease for greater than or equal to 24 weeks, per RECIST 1.1

Time frame:
2 years
Reported as:
Count of participants · Participants
Clinical Benefit Rate
ParticipantsNivolumab + Cabozantinib
Clinical Benefit Rate3
SecondaryProgression Free Survival Rate

Progression free survival is defined from the study entry to first documented evidence of disease progression by RECIST 1.1 or death of any cause, whichever occurs first. Patients alive with no progression are censored at the last disease assessment.

Time frame:
5 years
Reported as:
Median · months
Progression Free Survival Rate
monthsNivolumab + Cabozantinib
Progression Free Survival Rate3.6 (1.9 to 6.9)
SecondaryOverall Response Rate Per Immune Criteria

ORR will be determined according to immune-related response criteria (irRC). Per irRC, irComplete Response (irCR) refers to complete disappearance of all target lesions. irPartial Response (irPR) refers to decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all target and all new measurable target lesions (i.e., Percentage Change in Tumor Burden). ORR per irRC is irCR + irPR.

Time frame:
2 years
Reported as:
Count of participants · Participants
Overall Response Rate Per Immune Criteria
ParticipantsNivolumab + Cabozantinib
irPR1
irSD14
irPD2
not evaluable1

Adverse events

Collected over AE data were collected every cycle from the time of the first dose of the study treatment, through the end of the treatment. Vital status was followed even after patients were off treatment. AEs, including overall mortality, were observed up to 60 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Cabozantinib3/18 (16.7%)13/18 (72.2%)17/18 (94.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventNivolumab + Cabozantinib
Aspartate aminotransferase increasedInvestigations3/18
Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders3/18
FatigueGeneral disorders2/18
Alanine aminotransferase increasedInvestigations2/18
HypertensionVascular disorders2/18
Thromboembolic eventVascular disorders2/18
AnemiaBlood and lymphatic system disorders1/18
Endocrine disorders - Other, specifyEndocrine disorders1/18
Small intestinal perforationGastrointestinal disorders1/18
Edema trunkGeneral disorders1/18
Most frequent other events
Showing 10 of 68
Most frequent other events
EventNivolumab + Cabozantinib
Aspartate aminotransferase increasedInvestigations9/18
HypothyroidismEndocrine disorders7/18
FatigueGeneral disorders7/18
AnorexiaMetabolism and nutrition disorders7/18
Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders7/18
Alanine aminotransferase increasedInvestigations6/18
MyalgiaMusculoskeletal and connective tissue disorders6/18
DiarrheaGastrointestinal disorders5/18
Back painMusculoskeletal and connective tissue disorders5/18
HypertensionVascular disorders5/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nivolumab + Cabozantinib
Median58 (41 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Cabozantinib
Female18
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + Cabozantinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White15
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Nivolumab + Cabozantinib
United States18
ECOG
ECOG(Participants)Nivolumab + Cabozantinib
018
10
Stage at initial Diagnosis
Stage at initial Diagnosis(Participants)Nivolumab + Cabozantinib
I3
II6
III2
IV5
Unknown2
Disease free interval
Disease free interval(Participants)Nivolumab + Cabozantinib
De novo5
<=2 years4
>2 years5
Date missing4
Sites of disease -- lung pleural
Sites of disease -- lung pleural(Participants)Nivolumab + Cabozantinib
Count of participants6

19 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2019, 21 months.

Results were first posted in Dec 2021, 2 years 3 months after primary completion.

Of 1,071 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 21 months is below that.

Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2017
First posted
Oct 20, 2017
StartActual
Nov 30, 2017
Primary completionActual
Aug 30, 2019
CompletionActual
Aug 30, 2019
Results first posted
Dec 28, 2021
Last update
Dec 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03316586
Responsible party
Sara Tolaney (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Oct 20, 2017
Start date
Nov 30, 2017
Primary completion
Aug 30, 2019
Completion
Aug 30, 2019
Results posted
Dec 28, 2021
Last update
Dec 28, 2021

Study contacts

Sara Tolaney, MD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cabozantinib

Start the discussion